--- title: 'Senior Director, Commercial Excellence at Summit Therapeutics' canonical: 'https://feeny.ai/job/senior-director-commercial-excellence-summit-therapeutics-princeton-7yyt2trazq5s' type: 'job' last_seen: '2026-10-30' --- # Senior Director, Commercial Excellence at Summit Therapeutics - **Company:** Summit Therapeutics - **Location:** Princeton, NJ - **Compensation:** $217k–$271k - **Posted:** 2026-10-20 - **Last confirmed live:** 2026-10-30 - **Apply:** https://job-boards.greenhouse.io/summittherapeutics/jobs/4459562009 ## Job description About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland. Location: Princeton, NJ Overview of Role: The Senior Director, Commercial Excellence leads the headquarters side of Commercial Operations. This role builds and governs the systems, rules, and processes that Marketing, Market Access, Market Research, Finance, and Compliance all work from. This is the backbone of Commercial Operations: people, process, data, technology (the commercial systems the teams use), training, reporting, and analytics. That covers Marketing Operations, commercial data and technology, commercial training, incentive compensation, territory design, CRM, targeting and segmentation, roster management, and field reporting standards. The test for this role is simple: if the answer should be the same in every region, it belongs here. This leader is the single point of operational accountability for the function and partners with Field Excellence, which deploys this infrastructure as the dedicated operational partner to Sales. This role is also the functional partner for the Oncology Nurse Educators and Regional Marketing Directors, who report to Marketing, and the Field Reimbursement Managers, who report to Market Access. Ivonescimab is an intravenous, buy-and-bill oncology product, and Summit has not commercialized a product before, so this leader builds the function rather than inheriting it. This role does not carry a sales quota, does not receive territory-based sales incentive compensation, and does not conduct promotional activity with customers. This position reports to the Executive Director, Commercial Operations. Direct reports are the Director, Marketing Operations; Director, Commercial Data & Technology; Director, Commercial Excellence; and Director, Field Learning & Development. Role and Responsibilities: - Set the strategy, operating model, and annual plan for the function, built to support the ivonescimab launch, future indications, and the wider portfolio - Own the backbone of Commercial Operations (people, process, data, commercial technology, training, reporting, and analytics), and make sure each one is built, governed, and working for every function that relies on it - Serve as the primary operational counterpart to Marketing, Market Access, and Market Research, and resolve cross-functional operational conflicts before they reach the field - Serve as the functional partner for the Oncology Nurse Educators and Regional Marketing Directors (reporting to Marketing) and the Field Reimbursement Managers (reporting to Market Access), so their work runs on the same systems, definitions, and processes as the rest of the organization - Lead Marketing Operations through the Director, Marketing Operations, including promotional review workflow, material fulfillment, meetings and events, speaker programs, agency management, and budget - Oversee commercial data and technology through the Director, Commercial Data & Technology, including commercial data strategy, customer master data, the data warehouse, third-party data contracting, and the commercial systems the teams use, such as CRM. Set the business requirements for those systems and partner with IT on delivery - Oversee commercial training through the Director, Field Learning & Development, including training strategy, the launch training plan, the learning management system, and onboarding - Lead, through the Director, Commercial Excellence, incentive compensation design and governance, territory design and change governance, CRM business requirements and administration, targeting and segmentation methodology, and roster management and goal setting, so each one is compliant, accurate, and consistent nationally - Set field reporting standards, working from the metric definitions owned by the Director, Commercial Analytics & Information - Support Finance and Compliance on process governance, audit readiness, and Sunshine Act reporting - Partner with the National Senior Director, Field Excellence so field patterns come back to headquarters and get fixed once, nationally - Manage vendor relationships across all four teams, and build and own the annual budget for the function - Ensure compliance with legal, regulatory, and quality standards across all commercial operations activities - Lead, coach, and develop the four direct reports - All other duties as assigned Experience, Education and Specialized Knowledge and Skills: - Education: Bachelor's degree required. MBA or advanced degree preferred - Minimum of 12+ years of commercial or sales operations experience in the pharmaceutical or biotechnology industry. Field experience at a senior level. Product launch experience required. Oncology experience preferred. Experience with buy-and-bill products and the data limitations that come with them preferred - Specialized Knowledge and Skills: Deep understanding of market dynamics, data sources, field roles, and buying pathways, with oncology knowledge preferred. Detailed understanding of sales processes, sales data tracking, sales force automation, incentive compensation operations, and sales force alignments. Expertise in CRM platforms, incentive compensation modeling, and commercial analytics. Ability to develop and coach direct reports. Excellent verbal, written, and stakeholder management skills, with the ability to influence and manage expectations with sales management and cross-functional teams. Strong leadership, cross-functional collaboration, and project management skills. Able to excel in fast-paced, high-growth biotechnology environments - Travel: Approximately 25% domestic travel, including national and regional sales meetings This is the pay for this position Pay Transparency $217,000—$271,000 USD Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation. Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit. Summit Therapeutics Inc. is an Equal Opportunity Employer and takes pride in creating and maintaining diverse environment. We do not discriminate in recruitment, hiring, training or promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. ## About Summit Therapeutics ## Company Overview - **One-liner**: Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on discovering, developing, and commercializing novel bispecific antibody therapies, with its lead candidate ivonescimab targeting PD-1 and VEGF for multiple solid tumors. - **Entity Type**: Public (NASDAQ: SMMT) - **Headquarters**: Miami, Florida, USA (with additional offices in Palo Alto, CA; Princeton, NJ; Oxford, UK; and Dublin, Ireland) - **Founded**: 2003 - **Founders**: Not publicly disclosed on the company website; the company was founded in 2003. ## Core Business - **Primary industry**: Biopharmaceuticals / Oncology - **Target customers**: B2B (healthcare providers, patients, and caregivers) with a focus on resolving serious unmet medical needs in oncology - **Mission statement**: "To resolve serious, unmet medical needs for the betterment of overall human health." [smmttx.com](https://smmttx.com/company/about-us/default.aspx) ## Products & Services - **Ivonescimab (SMT112)**: A novel, potential first-in-class investigational bispecific antibody targeting both PD-1 and VEGF. It is designed to combine immunotherapy (PD-1 blockade) with anti-angiogenesis (VEGF blockade) into a single molecule. Currently being studied in several global Phase 3 clinical trials for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and head and neck squamous cell carcinoma (HNSCC). Licensed from Akeso, Inc. (HKEX: 9926.HK) for territories including the U.S., Canada, Europe, Japan, Latin America, the Middle East, and Africa. [smmttx.com](https://smmttx.com/pipeline/default.aspx) ## Market Standing - **Valuation/Market Cap**: Approximately $2.7 billion (as of recent data) [linkedin.com](https://www.linkedin.com/company/summit-therapeutics) - **Key Metric**: Annual revenue of approximately $705,000 (reported). The company is pre-commercialization and heavily investing in R&D. Total funding raised since IPO (2015) is not disclosed, but the company has a strong cash position from equity offerings. - **Notable Investors/Partners**: Akeso, Inc. (key licensing partner for ivonescimab). The company is publicly traded with institutional and retail investors. - **Growth Signals**: - Headcount grew 72.5% year-over-year to 244 employees. [linkedin.com](https://www.linkedin.com/company/summit-therapeutics) - Multiple global Phase 3 trials actively recruiting (HARMONi, HARMONi-3, HARMONi-7, HARMONi-GI3, ILLUMINE). - Over 4,000 patients have been treated with ivonescimab across all clinical trials globally. [smmttx.com](https://smmttx.com/pipeline/default.aspx) - Achieved Great Place to Work® Certification. [smmttx.com](https://smmttx.com/careers/careers-overview/default.aspx) ## Competitive Advantages - **Novel Mechanism**: Ivonescimab is a first-in-class bispecific antibody targeting both PD-1 and VEGF simultaneously, potentially offering superior efficacy and fewer side effects compared to combination therapies. - **Speed and Execution**: The company emphasizes "high-speed execution in commercialization" and has rapidly initiated multiple Phase 3 trials. - **Global Reach**: Licensed territories cover major markets (U.S., Canada, Europe, Japan, Latin America, Middle East, Africa) with a strong partner (Akeso) in the rest of the world. - **Strong Balance Sheet**: With a $2.7B market cap and public listing, the company has access to capital markets to fund its pipeline. ## Strategic Focus - **Current priorities**: Advancing ivonescimab through Phase 3 clinical trials across multiple solid tumor indications (NSCLC, CRC, HNSCC), with the goal of regulatory approval and commercialization. - **Future direction**: Expanding the pipeline into additional solid tumors and leveraging the bispecific platform for future therapies. The company is focused on becoming a leading oncology player. - **Near-term milestones**: Data readouts from ongoing Phase 3 trials, potential regulatory submissions, and building commercial infrastructure. ## Why Work Here - **Culture**: The company has achieved Great Place to Work® Certification, indicating a positive, supportive, and fulfilling work environment. Core values include Commitment to People, Integrity, Passion for Excellence, Purposeful Urgency, Accountability, and Collaboration. [smmttx.com](https://smmttx.com/careers/careers-overview/default.aspx) - **Work Environment**: Fast-paced, high-energy atmosphere focused on innovation and collaboration. The company emphasizes "making a significant difference in patients’ lives." - **Benefits (U.S.)**: - 401(k) with 6% employer match - Employee Stock Purchase Plan (ESPP) with 15% discount up to the annual federal limit - Flexible Spending Account - Commuter Benefit - Onsite lunch provided - **Benefits (U.K.)**: - Private Medical Insurance - Employee Assistance Program - Life Assurance Policy - Company Pension Contributions - ESPP - **Remote/Hybrid Policy**: Not explicitly stated, but multiple office locations suggest a hybrid or on-site presence is expected for many roles. - **Open Roles**: 25 active job postings (as of recent data) including Senior Director of Sales Operations, Clinical Scientists, Medical Science Liaisons, and Drug Product MSAT roles. [greenhouse.io](https://job-boards.greenhouse.io/summitherrapeutics) - **Headcount Growth**: 72.5% year-over-year growth signals a scaling organization with opportunities for career advancement. ## Sources 1. [smmttx.com - About Us](https://smmttx.com/company/about-us/default.aspx) 2. [smmttx.com - Investor Relations Overview](https://www.smmttx.com/overview/default.aspx) 3. [smmttx.com - Pipeline](https://smmttx.com/pipeline/default.aspx) 4. [smmttx.com - Careers Overview](https://smmttx.com/careers/careers-overview/default.aspx) 5. [linkedin.com - Summit Therapeutics Company Page](https://www.linkedin.com/company/summit-therapeutics) 6. [greenhouse.io - Summit Therapeutics Careers](https://job-boards.greenhouse.io/summitherrapeutics) ## Other roles at Summit Therapeutics - [Director, MSAT-Drug Product (US, UK, Ireland, or Switzerland)](https://feeny.ai/job/director-msat-drug-product-us-uk-ireland-or-switzerland-summit-therapeutics-r3tyakx42enr) — Princeton, NJ - [Senior Medical Science Liaison (Upper NY)](https://feeny.ai/job/senior-medical-science-liaison-upper-ny-summit-therapeutics-new-york-0m9ztt6s208s) — New York, NY - [Medical Writer, Medical Communications & Publications](https://feeny.ai/job/medical-writer-medical-communications-publications-summit-therapeutics-palo-alto-mq4p6tvcrxnt) — Palo Alto, CA - [Director, Medical Affairs Operations](https://feeny.ai/job/director-medical-affairs-operations-summit-therapeutics-princeton-qnwcxs9r0125) — Princeton, NJ - [Senior Manager, Externally Sponsored Research](https://feeny.ai/job/senior-manager-externally-sponsored-research-summit-therapeutics-palo-alto-h6g4ymrm7ret) — Palo Alto, CA - [Paralegal](https://feeny.ai/job/paralegal-summit-therapeutics-palo-alto-7crgxyrgt8ht) — Palo Alto, CA - [Director, Regulatory Affairs CMC](https://feeny.ai/job/director-regulatory-affairs-cmc-summit-therapeutics-remote-spf3wfkhxryb) - [Executive Director, Key Accounts Lead](https://feeny.ai/job/executive-director-key-accounts-lead-summit-therapeutics-field-fcy78qbyss0k) — Field, United States - [Senior Director, National Field Excellence](https://feeny.ai/job/senior-director-national-field-excellence-summit-therapeutics-united-states-tbfnrz5523j2) — United States - [Associate Director, Site Alliances and Strategy](https://feeny.ai/job/associate-director-site-alliances-and-strategy-summit-therapeutics-remote-k0p2pnwxn3bb)